Up a level
Export as [feed] Atom [feed] RSS 1.0 [feed] RSS 2.0
Group by: Item Type | Date | No Grouping
Number of items: 7.

Journal Article

Al-Sawaf, O., Robrecht, S., Bahlo, J., Fink, A. M., Cramer, P., Langerbeins, P., von Tresckow, J., Maurer, C., Kutsch, N., Lange, E., Kiehl, M., Fischer, K., Stilgenbauer, S., Wendtner, C-M, Goede, V, Hallek, M. and Eichhorst, B. (2018). Incidence and outcome of Richter transformation in chronic lymphocytic leukaemia (CLL) - A meta-analysis of German CLL Study Group (GCLLSG) trials. Oncol. Res. Treat., 41. S. 166 - 167. BASEL: KARGER. ISSN 2296-5262

Buehler, A., Wendtner, C-M, Kipps, T. J., Rassenti, L., Fraser, G. A. M., Michallet, A-S, Hillmen, P., Duerig, J., Gregory, S. A., Kalaycio, M., Aurran-Schleinitz, T., Trentin, L., Gribben, J. G., Chanan-Khan, A., Purse, B., Zhang, J., De Bedout, S., Mei, J., Hallek, M. and Stilgenbauer, S. (2016). Lenalidomide treatment and prognostic markers in relapsed or refractory chronic lymphocytic leukemia: data from the prospective, multicenter phase-II CLL-009 trial. Blood Cancer J., 6. LONDON: NATURE PUBLISHING GROUP. ISSN 2044-5385

Cramer, P., von Tresckow, J., Bahlo, J., Engelke, A., Langerbeins, P., Fink, A. -M., Wesselmann, J. S., Annolleck, T., Pflug, N., Kovacs, G., Fischer, K., Wendtner, C-M, Kreuzer, K. -A., Stilgenbauer, S., Boettcher, S., Eichhorst, B. and Hallek, M. (2015). CLL2-BIG, -BAG, -BCG and -BIO: A series of four phase-II trials evaluating a sequential regimen of combined targeted therapy aiming for a total eradication of MRD in treatment-naive and relapsed/refractory chronic lymphocytic leukemia (CLL). Oncol. Res. Treat., 38. S. 201 - 202. BASEL: KARGER. ISSN 2296-5262

Elter, T., James, R., Busch, R., Winkler, D., Ritgen, M., Boettcher, S., Kahl, C., Gassmann, W., Stauch, M., Hasan, I., Staib, P., Fischer, K., Fink, A-M, Bahlo, J., Buehler, A., Doehner, H., Wendtner, C-M, Stilgenbauer, S., Engert, A. and Hallek, M. (2012). Fludarabine and cyclophosphamide in combination with alemtuzumab in patients with primary high-risk, relapsed or refractory chronic lymphocytic leukemia. Leukemia, 26 (12). S. 2549 - 2554. LONDON: NATURE PUBLISHING GROUP. ISSN 0887-6924

Maurer, C., Langerbeins, P., Bahlo, J., Cramer, P., Fink, A. M., Pflug, N., Engelke, A., von Tresckow, J., Kovacs, G., Stilgenbauer, S., Wendtner, C-M, Mueller, L., Ritgen, M., Seiler, T., Fischer, K., Hallek, M. and Eichhorst, B. (2016). Effect of first-line treatment on second primary malignancies and Richter's transformation in patients with CLL. Leukemia, 30 (10). S. 2019 - 2026. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5551

Stilgenbauer, S., Chyla, B., Eichhorst, B., Schetelig, J., Munir, T., Hillmen, P., Seymour, J. F., Roberts, A. W., Coutre, S., Jurczak, W., Mulligan, S. P., Puvvada, S., Wendtner, C-M, Davids, M., Boeettcher, S., Cerri, E., Zhou, L., Popovic, R., Poteracki, M., Arzt, J., Kim, S. Y., Verdugo, M., Bhathena, A., Wierda, W. and Hallek, M. (2017). VENETOCLAX IN RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA WITH 17P DELETION: OUTCOME AND MINIMAL RESIDUAL DISEASE FROM THE FULL POPULATION OF THE PIVOTAL M13-982 TRIAL. Haematologica, 102. S. 311 - 313. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078

von Tresckow, J., Cramer, P., Bahlo, J., Engelke, A., Langerbeins, P., Fink, A. -M, Klaproth, H., Tausch, E., Fischer, K., Wendtner, C-M, Kreuzer, K. -A, Stilgenbauer, S., Boettcher, S., Eichhorst, B. and Hallek, M. (2016). CLL2-BIG - a sequential treatment regimen of Bendamustine followed by GA101 and Ibrutinib followed by Ibrutinib and GA101 maintenance in patients with Chronic Lymphocytic Leukemia (CLL): Interim results of a phase II-trial by the German CLL Study Group. Oncol. Res. Treat., 39. S. 121 - 122. BASEL: KARGER. ISSN 2296-5262

This list was generated on Fri Mar 29 00:14:54 2024 CET.